Literature DB >> 18262049

Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization.

Emma Samuelson1, Kristina Levan, Tatjana Adamovic, Göran Levan, György Horvath.   

Abstract

Determining what genes are actively involved in tumor development is important, because they may provide targets for directed therapy. Human tumors are greatly heterogeneous with respect to etiology and genetic background, which complicates the identification of common genetic aberrations. In contrast, genetic and environmental variation can be in part controlled in experimental animals, which facilitates identification of the important changes. In inbred BDII rats, which are genetically predisposed to endometrial adenocarcinomas (EAC), certain chromosome regions exhibit recurrent amplification in the tumors. Previous CGH analysis had shown that a subset of human EAC tumors exhibited increased copy numbers in the homologous chromosomal regions, located in human 2p21 approximately p25 and 7q21 approximately q31. Using fluorescence in situ hybridization analysis on imprints from 13 human EAC tumors, we determined the average copy numbers of each of 15 probes derived from cancer-related genes situated in these chromosome regions. Among the genes analyzed, those most often targeted by amplification were SDC1 and CYP1B1 in 2p21 approximately p25 and CDK6 and MET in 7q21 approximately q31, but all of the 15 genes tested were found to be amplified in at least two tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18262049     DOI: 10.1016/j.cancergencyto.2007.11.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.

Authors:  Tamer Refaat; Eric D Donnelly; Sean Sachdev; Vamsi Parimi; Samar El Achy; Prarthana Dalal; Mohamed Farouk; Natasha Berg; Irene Helenowski; Jeffrey P Gross; John Lurain; Jonathan B Strauss; Gayle Woloschak; Jian-Jun Wei; William Small
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

2.  Identification of a gene expression signature for survival prediction in type I endometrial carcinoma.

Authors:  Kristina Levan; Karolina Partheen; Lovisa Osterberg; Björn Olsson; Ulla Delle; Saskia Eklind; György Horvath
Journal:  Gene Expr       Date:  2010

Review 3.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

4.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Authors:  Federico Cappuzzo; Antonio Marchetti; Margaret Skokan; Elisa Rossi; Sujatha Gajapathy; Lara Felicioni; Maela Del Grammastro; Maria Grazia Sciarrotta; Fiamma Buttitta; Matteo Incarbone; Luca Toschi; Giovanna Finocchiaro; Annarita Destro; Luigi Terracciano; Massimo Roncalli; Marco Alloisio; Armando Santoro; Marileila Varella-Garcia
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

5.  The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.

Authors:  Zhenbo Tu; Johannes Schmoellerl; Odette Mariani; Yurong Zheng; Yi Hu; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  NPJ Breast Cancer       Date:  2021-05-31

6.  MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.

Authors:  H E Lee; M A Kim; H S Lee; E-J Jung; H-K Yang; B L Lee; Y-J Bang; W H Kim
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

Review 7.  Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.

Authors:  Elizabeth C Smyth; Francesco Sclafani; David Cunningham
Journal:  Onco Targets Ther       Date:  2014-06-12       Impact factor: 4.147

8.  The effect of first chromosome long arm duplication on survival of endometrial carcinoma.

Authors:  Erman Sever; Emek Doğer; Yiğit Çakıroğlu; Deniz Sünnetçi; Naci Çine; Hakan Savlı; İzzet Yücesoy
Journal:  Turk J Obstet Gynecol       Date:  2014-12-15

Review 9.  Modeling Endometrial Cancer: Past, Present, and Future.

Authors:  Tom Van Nyen; Cristian P Moiola; Eva Colas; Daniela Annibali; Frédéric Amant
Journal:  Int J Mol Sci       Date:  2018-08-09       Impact factor: 5.923

10.  Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.

Authors:  G Minuti; F Cappuzzo; R Duchnowska; J Jassem; A Fabi; T O'Brien; A D Mendoza; L Landi; W Biernat; B Czartoryska-Arłukowicz; T Jankowski; D Zuziak; J Zok; B Szostakiewicz; M Foszczyńska-Kłoda; A Tempińska-Szałach; E Rossi; M Varella-Garcia
Journal:  Br J Cancer       Date:  2012-07-31       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.